Alchemia hits high for year

Investors hope the biotech will post its first profit for 2013-14 on growing royalty payments from its distribution partner Dr Reddy and its ongoing pipeline.

Biotech Alchemia (ACL) hit its highest level this year as investors buy into hopes that the current financial year would mark an important milestone for the company.

Alchemia is expected to post a maiden profit in 2013-14 thanks to growing royalty payments from its distribution partner Dr Reddy, which has licenced Alchemia’s technology to manufacture a generic anti-coagulant drug, fondaparinux.


SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles